Additional file 4: of Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
Cheng‐Lung Hsu, Hsin-Pai Li, Hsien-Chi Fan, Alex Y. Chang(Cornell University), Yuan‐Ming Yeh(Chang Gung Memorial Hospital), Yin‐Kai Chao(Chang Gung University), Yu‐Sun Chang(Chang Gung University), An-Chi Lin, Li‐Yu Lee(Chang Gung University), Chia‐Hsun Hsieh(Chang Gung University), Yen‐Jung Lu, Chun‐Nan Yeh(Chang Gung University), Yi-Ru Lai, Hung‐Ming Wang, Ngan‐Ming Tsang, Yenlin Huang(Chang Gung University), Kar‐Wai Lui, Meiyuan Huang(Zhuzhou Central Hospital), Lang‐Ming Chi, Kai‐Ping Chang(Chang Gung University), Tung‐Liang Lin(Chang Gung University), Yung‐Chia Kuo(Linkou Chang Gung Memorial Hospital)
Cited by 0
Related Papers
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
|Journal of Clinical Oncology|2018|473
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
|Lung Cancer|2010|441
Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia
|Science Translational Medicine|2017|381